-
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
de Jonge, A. V., Bult, J. A. A., Karssing, D. F. E., Nijland, M., Chamuleau, M. E. D. & Brink, M., 1 Dec 2024, In: Blood Cancer Journal. 14, 1, 2.Research output: Contribution to journal › Article › Academic › peer-review
-
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
de Jonge, A. V., van Werkhoven, E., Dinmohamed, A. G., Nijland, M., Zwinderman, A. H., Bossuyt, P. M., Veldhuis, M. S., Rutten, E. G. G. M., Mous, R., Vermaat, J. S. P., Sandberg, Y., de Jongh, E., Bilgin, Y. M., Boersma, R., Koene, H., Kersten, M. J., de Jong, D. & Chamuleau, M. E. D., 1 Dec 2023, In: Blood Cancer Journal. 13, 1, 85.Research output: Contribution to journal › Article › Academic › peer-review
-
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., Sendecki, J., Wong, A., Verona, R. I., Sonneveld, P., Zweegman, S., Adams, H. C., Mutis, T. & van de Donk, N. W. C. J., 27 Apr 2021, In: Blood. 5, 8, p. 2196-2215 20 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications